[go: up one dir, main page]

DK3353196T5 - Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1 - Google Patents

Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1 Download PDF

Info

Publication number
DK3353196T5
DK3353196T5 DK16775121.3T DK16775121T DK3353196T5 DK 3353196 T5 DK3353196 T5 DK 3353196T5 DK 16775121 T DK16775121 T DK 16775121T DK 3353196 T5 DK3353196 T5 DK 3353196T5
Authority
DK
Denmark
Prior art keywords
neuropilin
leptin
inhibiting
binding
polypeptides capable
Prior art date
Application number
DK16775121.3T
Other languages
English (en)
Other versions
DK3353196T3 (da
Inventor
Olivier Hermine
Carmen Garrido-Fleury
Guillaume Marcion
Matthieu Montes
Renaud Seigneuric
Zakia Belaid-Choucair
Original Assignee
Inst Nat Sante Rech Med
Fond Imagine
Assist Publique Hopitaux De Paris Ap Hp
Univ Paris Cite
Centre Nat Rech Scient
Univ Bourgogne
Cnam Conservatoire Nat Des Arts Et Metiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Fond Imagine, Assist Publique Hopitaux De Paris Ap Hp, Univ Paris Cite, Centre Nat Rech Scient, Univ Bourgogne, Cnam Conservatoire Nat Des Arts Et Metiers filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK3353196T3 publication Critical patent/DK3353196T3/da
Publication of DK3353196T5 publication Critical patent/DK3353196T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16775121.3T 2015-09-22 2016-09-21 Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1 DK3353196T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306471 2015-09-22
PCT/EP2016/072352 WO2017050793A1 (en) 2015-09-22 2016-09-21 Polypeptides capable of inhibiting the binding between leptin and neuropilin-1

Publications (2)

Publication Number Publication Date
DK3353196T3 DK3353196T3 (da) 2023-02-20
DK3353196T5 true DK3353196T5 (da) 2024-09-30

Family

ID=54199609

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16775121.3T DK3353196T5 (da) 2015-09-22 2016-09-21 Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1

Country Status (5)

Country Link
US (1) US10647752B2 (da)
EP (1) EP3353196B1 (da)
DK (1) DK3353196T5 (da)
ES (1) ES2940360T3 (da)
WO (1) WO2017050793A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4403578A1 (en) 2023-01-19 2024-07-24 Theranovir Antibody aginst a glycosaminoglycan-modified neuropilin-1 epitope and methods of use thereof
AU2024209035A1 (en) 2023-01-19 2025-08-07 Theranovir Neuropilin-1-peptide based antibody, highliting new epitope associated to glycosaminoglycan-modified neuropilin-1 and methods of use thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2763986A (en) * 1950-10-27 1956-09-25 Bendix Aviat Corp Emergency control system, regulator and computer mechanism
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US20050038609A1 (en) * 1992-03-25 2005-02-17 Benner Steven Albert Evolution-based functional genomics
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
JP3866760B2 (ja) 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997016550A1 (en) * 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Polypeptide fragments derived from the obese gene product
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CN100480269C (zh) 1997-04-07 2009-04-22 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US9091651B2 (en) * 2011-12-21 2015-07-28 Integrated Diagnostics, Inc. Selected reaction monitoring assays
HK1206601A1 (en) * 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
JP6666848B2 (ja) 2014-02-18 2020-03-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｎｒｐ−１／ｏｂｒ複合体シグナル伝達経路により媒介される疾患の処置のための方法及び医薬組成物
US10738122B2 (en) * 2014-09-05 2020-08-11 Rsem, Limited Partnership Compositions and methods for treating and preventing inflammation

Also Published As

Publication number Publication date
WO2017050793A1 (en) 2017-03-30
US10647752B2 (en) 2020-05-12
ES2940360T3 (es) 2023-05-05
EP3353196A1 (en) 2018-08-01
EP3353196B1 (en) 2022-12-21
US20180230189A1 (en) 2018-08-16
DK3353196T3 (da) 2023-02-20

Similar Documents

Publication Publication Date Title
IL282704A (en) De novo binding domain containing polypeptides and uses thereof
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3537765T3 (da) Fremgangsmåde og indretning til omskiftning
DK3347472T3 (da) Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf.
DK3398022T3 (da) Systemer og fremgangsmåder til tilpasning af uav-bane
DK3265947T3 (da) Fremgangsmåde og system til kryptering
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3370534T3 (da) Anordning og fremgangsmåde til sprøjtetørring
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
DK3157552T3 (da) Syntac-polypeptider og anvendelser deraf
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3212189T3 (da) Substituerede chromaner og fremgangsmåde til anvendelse deraf
DK3606760T3 (da) Indretning og fremgangsmåde til belægning af overflader
DK3319434T3 (da) Herbicidsammensætning, der omfatter cinmethylin og pethoxamid
DK3161124T3 (da) Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf
DK3145945T3 (da) Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf
DK3319612T3 (da) Oxysteroler og fremgansmåder til anvendelse derfor
DK3704227T3 (da) Sammensætning og fremgangsmåde
DK3626602T3 (da) Styreanordning og fremgangsmåde til styreanordningen
DK3330258T3 (da) 1, 3, 5-triazinderivat og fremgangsmåde til anvendelse af samme
DK3353168T3 (da) Forbindelser og fremgangsmåder til at inhibere jak
DK4293009T3 (da) Fenfluraminsammensætninger og fremgangsmåder til fremstilling af samme